Company / Working Capital
INOVIO PHARMACEUTICALS, INC. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$17.5M
FY2025
5-year range
$17.5M / $382.7M
FY2021-FY2025
Trend
-72.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 5 consecutive years, from $429M in FY2020 to $17M in FY2025.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of -47.3%.
Declined from $111M to $17M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -56.9%
- 5-Year CAGR
- -47.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- INOVIO PHARMACEUTICALS, INC.'s working capital has declined for 5 consecutive years.
- 5-year CAGR of -47.3%, indicating a declining trend.
- In FY2025, working capital decreased 72.1% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.5M | -72.1% |
| FY2024 | $62.5M | -43.5% |
| FY2023 | $110.5M | -49.4% |
| FY2022 | $218.4M | -42.9% |
| FY2021 | $382.7M | -10.9% |
| FY2020 | $429.5M | +590.3% |
| FY2019 | $62.2M | +18.5% |
| FY2018 | $52.5M | -49.0% |
| FY2017 | $103.0M | +27.5% |
| FY2016 | $80.8M | -42.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026